Article
Biology
Min Seung Lee, So Hyun Lim, Ah-Ran Yu, Chi Yeon Hwang, Insug Kang, Eui-Ju Yeo
Summary: The study showed that proteasome inhibitors bortezomib and carfilzomib induce apoptosis and endoplasmic reticulum stress in melanoma cells, leading to potential therapeutic effects against melanoma. Combination therapy of carfilzomib and bortezomib at submaximal concentrations synergistically reduced tumor growth, suggesting a promising strategy for the treatment of melanoma.
Article
Biochemistry & Molecular Biology
Lukas M. Bollmann, Alexander J. Skerhut, Yodita Asfaha, Nadine Horstick, Helmut Hanenberg, Alexandra Hamacher, Thomas Kurz, Matthias U. Kassack
Summary: This study introduces a novel highly selective HDAC inhibitor, YAK540, and demonstrates its synergistic cytotoxic effect and proapoptotic effect when combined with the proteasome inhibitor BTZ. The cytotoxicity of the YAK540 and BTZ combination is significantly lower in non-cancer cells compared to leukemia cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Jianhao Liu, Ruogang Zhao, Xiaowen Jiang, Zhaohuan Li, Bo Zhang
Summary: Bortezomib is a proteasome inhibitor that has been approved for the treatment of multiple myeloma and other hematological cancers. However, its limited specificity, poor permeability, and low bioavailability hinder its applications. Recent research has focused on the development of BTZ-based drug delivery systems.
Article
Virology
Alecia Alto, Sekar Natesampillai, Aswath P. Chandrasekar, Ashton Krogman, Anisha Misra, F. N. U. Shweta, Caitlin VanLith, Joseph D. Yao, Nathan W. Cummins, Andrew D. Badley
Summary: The combination treatment of venetoclax and ixazomib shows enhanced killing of latently HIV-infected cells and greater reduction in HIV replication in vitro, but results in unacceptable toxicity in primary cells. Further investigation is needed to find a clinically relevant latency reversal agent for combination therapy with venetoclax to reduce the HIV reservoir.
JOURNAL OF VIROLOGY
(2021)
Article
Biochemistry & Molecular Biology
Kyota Ishii, Mayuko Hido, Misaki Sakamura, Nantiga Virgona, Tomohiro Yano
Summary: This study demonstrated that T3, TOS, and T3E enhance the sensitivity of the proteasome inhibitor BTZ in solid cancers by modulating the activity of NFE2L1. Inactivation of NFE2L1 by T3, TOS, and T3E is essential to potentiate the cytotoxic effect of BTZ in solid cancers.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Gregoire Quinet, Wendy Xolalpa, Diana Reyes-Garau, Nuria Profitos-Peleja, Mikel Azkargorta, Laurie Ceccato, Maria Gonzalez-Santamarta, Maria Marsal, Jordi Andilla, Fabienne Aillet, Francesc Bosch, Felix Elortza, Pablo Loza-Alvarez, Brigitte Sola, Olivier Coux, Rune Matthiesen, Gael Roue, Manuel S. Rodriguez
Summary: The research identified an enrichment of autophagy-lysosome system (ALS) components in bortezomib (BTZ)-resistant cells in mantle cell lymphoma (MCL) patients. By blocking proteaphagy, the normal proteasomal activity was reactivated and the BTZ antitumor effect was restored in vitro and in vivo models of BTZ resistance. These findings suggest a proteolytic switch from the ubiquitin-proteasome system (UPS) to ALS in B-cell lymphoma refractory to proteasome inhibition, opening up new therapeutic avenues for treatment-resistant tumors.
Article
Biochemistry & Molecular Biology
Zohreh Jahani, Jamshid Davoodi
Summary: Metformin, an anti-diabetic drug, has a dual effect on breast cancer cell lines by both upregulating and enhancing the degradation of certain proteins during mTORC1 inhibition.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2022)
Article
Oncology
Kayhan Mehdizadeh, Farangis Ataei, Saman Hosseinkhani
Summary: The combination of proteasome inhibitor and Docetaxel shows enhanced cytotoxic effects on MCF7 breast cancer cells, delaying cell growth, and increasing ROS production. Cells overexpressing Apaf-1 are more susceptible to Docetaxel, but the addition of proteasome inhibitor does not significantly improve the response.
Review
Immunology
Naeemeh Khalesi, Shahla Korani, Mitra Korani, Thomas P. Johnston, Amirhossein Sahebkar
Summary: Autoimmune diseases are conditions where the immune system cannot distinguish self from non-self, leading to tissue injury. The proteasome inhibitor bortezomib has shown effectiveness in treating patients with ADs resistant to conventional therapies.
INFLAMMOPHARMACOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Mingyu Chen, Sarun Juengpanich, Shijie Li, Win Topatana, Ziyi Lu, Qiang Zheng, Jiasheng Cao, Jiahao Hu, Esther Chan, Lidan Hou, Jiang Chen, Fang Chen, Yu Liu, Sukanda Jiansirisomboon, Zhen Gu, Suparat Tongpeng, Xiujun Cai
Summary: This study reports on a targeted therapy for gallbladder cancer using pH-responsive nanoparticles encapsulating bortezomib and mediated by estrogen-induced endocytosis. The treatment effectively inhibits proteasomes and induces apoptosis under tumor microenvironment and laser irradiation.
Article
Chemistry, Multidisciplinary
Suresh Udutha, Roshan M. Borkar, G. Shankar, T. Sony, Aishwarya Jala, E. Vamshi Krisna, T. Kiran Kumar, S. Misra, S. Prabhakar, R. Srinivas
Summary: Bortezomib (BTZ) is a potent reversible inhibitor of proteasome used in the treatment of multiple myeloma. Studies on its degradation under various conditions identified 16 degradation products, with some showing toxicity in vitro cell toxicity tests. Further in silico studies suggested potential hepatotoxicity and genotoxicity of BTZ and its degradation products.
NEW JOURNAL OF CHEMISTRY
(2021)
Article
Multidisciplinary Sciences
Franziska Weiner, Jan Torben Schille, Jens Ingo Hein, Xiao-Feng Wu, Matthias Beller, Christian Junghanss, Hugo Murua Escobar, Ingo Nolte
Summary: FX-9, a novel potential chemotherapeutic agent, shows antiproliferative effects against hematologic and prostate cancer cell lines. Combining FX-9 with azacitidine or carboplatin offers synergistic/additive efficacy against prostate adenocarcinoma cell lines in vitro.
Article
Oncology
Tiit Ord, Daima Ord, Minna U. Kaikkonen, Tonis Ord
Summary: Proteasome inhibitors, like bortezomib, are used in the treatment of certain cancers, but resistance may develop. This study explores the molecular mechanisms behind liver cancer cells' resistance to bortezomib, focusing on the role of the eIF2 alpha-ATF4 stress response pathway and the pseudokinase TRIB3. Their findings suggest that TRIB3, by limiting ATF4 activity, contributes to bortezomib resistance, while pharmacological activation of eIF2 alpha-ATF4 pathway can sensitize cells to bortezomib.
Article
Nanoscience & Nanotechnology
Guangtao Gao, Yong Xu, Jingjing Gan, Xinya Cao, Xiaoqing Dong, Mengkun Fang, Ying Du, Peipei Xu, Junyi Che, Bing Chen
Summary: This study reports a targeting strategy for multiple myeloma using platelet membrane-coated nanoparticles encapsulating BTZ. Compared to non-targeted BTZ, the nanoparticle system shows significant improvements in selectivity, cellular uptake, and anticancer effects, demonstrating a high potential for multiple myeloma patients.
Article
Pharmacology & Pharmacy
Xiuhui Chen, Yanhong Chen, Yitao Ou, Wenjie Min, Shuli Liang, Lei Hua, Yinghua Zhou, Cheng Zhang, Peifeng Chen, Zhongjin Yang, Wenhui Hu, Ping Sun
Summary: The abnormal activation of NLRP3 inflammasome is important in the pathogenesis of psoriasis. Bortezomib, a marketed drug for treating multiple myeloma, specifically inhibits NLRP3 inflammasome activation and may be a potential therapeutic drug for psoriasis.
BIOCHEMICAL PHARMACOLOGY
(2022)